slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,381-226,410
Pages 10,126
Rows per page 30
Component
226,381-226,410 of 303,780
15
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · Action1 hit
16
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · Action1 hit
17
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations Beat · Action1 hit
19
The slide uses a laurel wreath motif to frame each award entry.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
20
IBEX | Results Presentation Deck | 25 slidesIBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
21
The slide includes a legend mapping specific adjustments (A, B, C, D) to their descriptions.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
22
Includes specific footnotes A, B, C, and D explaining non-recurring and share-based adjustments.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
23
Financial table showing quarterly performance for ibex.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
24
The table includes adjustments for non-recurring expenses, warrant contra revenue, foreign currency fluctuations, asset sales, share-based compensation, and lease terminations.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
25
The table provides a detailed breakdown of adjustments including interest, taxes, D&A, and various non-recurring or non-cash items.IBEX | Results Presentation Deck | 25 slides · ibex
Conference presentation Investor relations 1 hit
01
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
02
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
03
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates across different clinical phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
12
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
15
Includes clinical trial screening data for specific cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
16
The slide uses a table to compare patient demographics and clinical characteristics across different cancer types, specifically focusing on the sufficiency of the melanoma cohort for further development.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
21
Data cut-off Sep 30, 2023. N=16 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses a matrix structure to define the patient population and market opportunity.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
38
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
41
The slide features a high-quality photograph of a scientist handling cryogenic materials, reinforcing the 'off-the-shelf' (frozen/stored) nature of the product.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
44
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
56
The chart uses a broken x-axis between -29 and 0. The legend indicates four distinct treatment groups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit